

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code : 2666)

UNAUDITED OPERATION SUMMARY OF THE GROUP FOR THE FIRST QUARTER OF 2024

This announcement sets out the unaudited operation summary of Genertec Universal Medical Group Company Limited (the “**Company**”), together with its subsidiaries (the “**Group**”), for the first quarter ended 31 March 2024.

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

During the first quarter of 2024, the Group promoted business development of all sectors and achieved a stable growth in operating results: the revenue of the Group decreased slightly by approximately 1.6% as compared with the corresponding period of 2023, while the profit for the period increased by approximately 5.0% as compared with the corresponding period of 2023. Within the healthcare business, the revenue increased by approximately 4.9% as compared with the corresponding period of 2023, and the profit for the period increased by approximately 36.9% as compared with the corresponding period of 2023. The significant growth of the healthcare business was driven by the steady improvement in the operational quality of integrated healthcare business and the substantial increase in the newly consolidated revenue from equipment life cycle management business. Among them, the revenue from equipment life cycle management business amounted to RMB99.0 million, representing an increase of approximately 314.8% as compared with the corresponding period of 2023, with the profit for the period of RMB13.2 million, representing an increase of approximately 614.8% as compared with the corresponding period of 2023.

In respect of integrated healthcare business, focusing on the primary goals of “comfortable environment, top-notch services, advanced technology and efficient operation”, the Group continued to empower the development of the hospitals run by state-owned enterprises and improve operation

efficiency and effectiveness. The member medical institutions managed by the Group performed well in the first quarter of 2024: outpatient and emergency visits increased by approximately 6.1% as compared with the corresponding period of 2023, while the number of inpatients increased by approximately 9.2% as compared with the corresponding period of 2023.

In respect of specialties and healthcare industry, with the business foundation and professional core talent team of our own hospital group, the Group strived to build replicable capabilities of specialties and industry operation, so as to create new profit growth drivers for the Company. All projects within this segment are progressing as planned, including business expansion and external acquisitions. For specialties, the Group completed the acquisition of 100% equity interests of five hemodialysis centers of Hainan Kangprui Hospital Management Co., Ltd.(海南康普瑞醫院管理有限公司), and continued to advance the acquisition projects of other specialist hospitals and hemodialysis centres. For the life circle management of equipment, the Group acquired controlling stakes in Shandong Tuozhuang Medical Technology Co., Ltd. (山東拓莊醫療科技有限公司) and Beijing Zhongtaihe Medical Device Co., Ltd.(北京眾泰合醫療器械有限公司). For the medical digitization, the Group completed the acquisition of a controlling stake in ShanDong JB Soft & Info Technology Co., Ltd. (山東青鳥軟通信息技術股份有限公司). In addition, acquisition projects of specialized medical institutions such as ophthalmology and oncology centers, as well as other industry companies, are also progressing smoothly.

In respect of finance business, the Group always took risk control as a top priority, promoted the investment of interest-generating assets in an orderly manner, and were committed to ensuring quality project development for our customers. On the cost side, by closely monitoring the market trends and ensuring reasonable liquidity and a stable debt maturity structure, we actively utilized various financing tools both domestically and internationally to effectively control overall financing costs. As at 31 March 2024, interest-earning assets continued to increase as compared with the end of 2023, with slight increase in net interest margin and net interest spread. Asset quality still remained at a good level, and the provision coverage remained prudent.

In addition, references are made to the Company's announcements dated 20 December 2021, 30 May 2022, 6 July 2022, 5 September 2022, 13 January 2023, 4 April 2023, and 29 August 2023 in relation to the issuance of the medium-term notes with an aggregate principal amount of RMB3.50 billion in the inter-bank market in the People's Republic of China (the "PRC") by China Universal Leasing Co., Ltd. (中國環球租賃有限公司) ("**Universal Leasing**"), a wholly-owned subsidiary of the Company. In accordance with the relevant laws and regulations of the PRC, the unaudited consolidated financial information of Universal Leasing for the three months ended 31 March 2024 (the "**Universal Leasing Consolidated Financial Information**") has been published on the websites of Shanghai Clearing House (www.shclearing.com) and China Foreign Exchange Trade System (www.chinamoney.com.cn) on 30 April 2024. The Company's board of directors would like to draw the attention of its shareholders and investors to the following principal financial data of Universal Leasing:

PRINCIPAL CONSOLIDATED FINANCIAL DATA OF UNIVERSAL LEASING

*Unit: Thousand Yuan
Currency: RMB*

**As at 31 March 2024
(unaudited)**

**As at 31 December 2023
(audited)**

Total assets	85,197,045	80,140,491
Total equity	21,509,377	20,946,601
	For the three months ended 31 March 2024 (unaudited)	For the three months ended 31 March 2023 (unaudited)
Operating income	3,192,531	3,243,589
Profit for the period	498,261	471,731
Net cash flows (used in) operating activities	(5,119,043)	(5,733,987)

The Company hereby reminds investors that the above unaudited operation summary for the first quarter ended 31 March 2024 was prepared based on the Group's internal figures and management accounts which have not been reviewed or audited by the auditors of the Group. The Universal Leasing Consolidated Financial Information was prepared in accordance with the General Accepted Accounting Principles of the PRC, which may require adjustment during the course of auditing of the financial results of the Group, and the information contained therein is limited solely to the operation of Universal Leasing, which does not provide a full picture of the operation status of the Group or comparison with the Group.

Investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
**Genertec Universal Medical Group Company
Limited**
通用環球醫療集團有限公司
Peng Jiahong
Chairwoman of the Board

Beijing, PRC, 30 April 2024

As at the date of this announcement, the executive directors of the Company are Ms. Peng Jiahong (Chairwoman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive directors of the Company are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.